早期强化应用阿托伐他汀在治疗急性心肌梗死中的作用

Effect of early enhancing application of atorvastatin in treatment of acute myocardial infarction

目的探讨早期强化应用阿托伐他汀对急性心肌梗死(AMI)的治疗效果。方法选择我院2015年5月~2016年5月收治的90例AMI患者,对其临床资料进行回顾分析,将采用常规治疗方案的45例患者作为对照组,将接受早期阿托伐他汀强化治疗的45例患者作为研究组。经过4周的治疗后,比较两组患者治疗前后内皮素(ET-1)、一氧化氮(NO)以及血脂指标变化情况,同时对两组的心血管事件发生率和不良反应发生率进行统计比较。结果经治疗后,两组患者TG、TC、LDL-C、ET-1以及NO较治疗前均有显著改善(P<0.05),其中研究组患者的TG、ET-1以及NO改善程度要显著优于对照组(P<0.05);治疗期间研究组与对照组的心血管事件发生率分别为24.44%和68.89%,差异有统计学意义(P<0.05),其中研究组心绞痛与心力衰竭的发生率明显低于对照组(P<0.05);两组患者在治疗期间发生的不良反应主要有乏力、肝功能异常、消化道反应、肌痛,其中研究组不良反应发生率为22.22%,对照组为28.89%,差异无统计学意义(P>0.05)。结论早期强化应用阿托伐他汀治疗AMI对于优化患者血脂水平,减轻炎症反应降低心血管事件发生率具有显著效果,同时安全性也较高,适合在临床上进行推广。

Objective To explore curative effect of early enhancing application of atorvastatin in treatment of acutemyocardial infarction(AMI).Methods90AMI patients who were admitted to our hospital from May2015to May2016were selected and their clinical data were retrospectively analyzed.45patients who were given routine treatmentscheme were set as the control group while45patients who were given atorvastatin for early intensive treatment wereset as the research group.After4-week treatment,endothelin(ET-1),nitric oxide(NO)and blood lipid index before andafter treatment of patients in two groups were compared.In addition,incidences of cardiovascular events and adversereactions of two groups were statistically compared.Results After treatment,TG,TC,LDL-C,ET-1and NO of patientsin two groups were all significantly improved compared with those before treatment(P<0.05).Improvement ofTG,ET-1and NO of patients in the research group were significantly better than those of the control group(P<0.05).Incidences of cardiovascular events of the research group and the control group during treatment were respectively24.44%and68.89%.There were significant differences between two groups(P<0.05).Of which,incidence of anginapectoris and heart failure in the research group was significantly lower than that of the control group(P<0.05).Duringtreatment,adverse reactions of patients in two groups were mainly fatigue,abnormal liver function,gastrointestinalreaction and myalgia.Incidence of adverse reactions in the research group and the control group was respectively22.22%and28.89%.There was no significant difference between two groups(P>0.05).Conclusion early enhancingapplication of atorvastatin in treatment of AMI has a significant effect on optimizing blood lipid level,reducinginflammatory response and reducing incidence of cardiovascular events.In addition,it has higher safety,which is suitedfor clinical promotion.